Clinical MilestonesThe company is on track to get to its key milestone, the P2a data for AJ201 in Spinal Bulbar Muscular Atrophy, which is expected in the coming months.

Regulatory PathwayPositive data indicative of potential clinical improvement should pave the way to meet with the FDA to determine next steps.

Bears Say

Capital RequirementsThe company is going to need to raise capital soon, either before or after the data, given the short runway.

Financial PerformanceAvenue reported 2Q24 results with a net loss of ($2.7M) and ended the period with $4.9M in cash on the balance sheet.

Financing NeedsA P2a is planned, but additional financing is needed for which Avenue is exploring its options, including potential partnerships.

Avenue Therapeutics News

Avenue Therapeutics shareholders elect directors, ratify KPMG auditor

Avenue Therapeutics ( ($ATXI) ) has provided an update. At its 2025 annual meeting of stockholders held virtually...

12d ago

ATXI

Avenue Therapeutics Announces 2025 Annual Meeting Date

Avenue Therapeutics ( ($ATXI) ) has issued an update. Avenue Therapeutics, Inc. has announced December 30, 2025, as...

2M ago

ATXI

Avenue Therapeutics Reports Improved Financials Amid Challenges

Avenue Therapeutics ( ($ATXI) ) has released its Q3 earnings. Here is a breakdown of the information Avenue...

2M ago

ATXI

Avenue Therapeutics Sells Baergic Bio to Axsome

The latest announcement is out from Avenue Therapeutics ( ($ATXI) ). On November 5, 2025, Avenue Therapeutics and...

2M ago

ATXI

Avenue Therapeutics announces Baergic Bio acquisition by Axsome

Avenue Therapeutics (ATXI) subsidiary, Baergic Bio announced that Avenue has entered into an agreement for Baergic to be...

2M ago

AZN

ATXI

Axsome enters agreement to obtain exclusive global rights to AZD7325

Axsome Therapeutics (AXSM) (AZXM) entered into an agreement to obtain exclusive global rights to AZD7325, a novel oral...

2M ago

AZN

ATXI

Avenue Therapeutics Reports Positive Earnings Amid Challenges

Avenue Therapeutics ( ($ATXI) ) has released its Q2 earnings. Here is a breakdown of the information Avenue...

5M ago

ATXI

Avenue Therapeutics Ends License Agreement with AnnJi

An update from Avenue Therapeutics ( ($ATXI) ) is now available. On April 24, 2025, Avenue Therapeutics and...

9M ago

ATXI

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

10M ago

INO

ARCT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

10M ago

PLX

SLS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

12M ago

ATXI

BTAI

Avenue Therapeutics files $35M mixed securities shelf

17:16 EST Avenue Therapeutics (ATXI) files $35M mixed securities shelf Published first on TheFly – the ultimate source...

1y ago

ATXI

Avenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c)

As of September 30 cash and cash equivalents totaled $2.6M , compared to $4.9M at June 30 and...

1y ago

ATXI

Avenue Therapeutics Incentive Plan Awards Key Executives

An update from Avenue Therapeutics ( ($ATXI) ) is now available. Avenue Therapeutics, Inc. has awarded equity incentives...

1y ago

ATXI

ATXI FAQ

What was Avenue Therapeutics Inc’s price range in the past 12 months?

Avenue Therapeutics Inc lowest stock price was $0.17 and its highest was $2.06 in the past 12 months.

What is Avenue Therapeutics Inc’s market cap?

Avenue Therapeutics Inc’s market cap is $2.39M.

When is Avenue Therapeutics Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Avenue Therapeutics Inc’s earnings last quarter?

Currently, no data Available

Is Avenue Therapeutics Inc overvalued?

According to Wall Street analysts Avenue Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Avenue Therapeutics Inc pay dividends?

Avenue Therapeutics Inc does not currently pay dividends.

What is Avenue Therapeutics Inc’s EPS estimate?

Avenue Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Avenue Therapeutics Inc have?

Avenue Therapeutics Inc has 3,183,426 shares outstanding.

What happened to Avenue Therapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Avenue Therapeutics Inc?

Currently, no hedge funds are holding shares in ATXI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Avenue Therapeutics Inc

Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. The company's core product includes intravenous (IV) tramadol, which is designed to treat moderate to moderately severe postoperative pain. Avenue Therapeutics operates within the healthcare sector, with a focus on pain management solutions.